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Abstract
Background: Programs that integrate tuberculosis (TB) and human immunodeficiency virus (HIV) treatment aim to
provide efficient treatment services and maximize successful treatment outcomes through the delivery of both TB
and HIV treatment by one provider at the same time and location. However, multi-drug resistant tuberculosis (MDR-
TB) is more difficult to treat as compared to drug-sensitive TB, and in low- and middle-income countries (LMICs),
the potential of programs integrating TB/HIV treatment to sustain favourable MDR-TB treatment outcomes is poorly
elucidated. The objective of this review is to perform a systematic collection, critical appraisal and synthesis of
existing evidence on therapeutic outcomes of MDR-TB and their predictors among adults receiving integrated
treatment for TB/HIV in LMICs.
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Methods: A systematic review of quantitative evidence from observational cohort studies will be performed. MEDL
INE, Embase, and Global Health electronic databases will be searched for relevant studies published from March
2004 to December 2019. Two investigators will independently screen the search output, review the eligible studies,
and assess the quality of the eligible studies using quality assessment tools of the National Heart Lung and Blood
Institute. Random-effects meta-analysis will be used to obtain summary estimates. Heterogeneity across studies will
be assessed using the I2 statistic. The confidence in the summary estimates will be rated using the Grading of
Recommendations, Assessment, Development and Evaluation (GRADE) approach. The final review will be reported
following the guidelines of the Preferred Reporting System for Systematic Reviews and Meta-analysis, presented at
scientific conferences and published in a peer-reviewed journal.
Discussion: This study is expected to report the performance of integrated TB/HIV treatment programs as regards
their potential to uphold successful MDR-TB treatment outcomes in LMICs. Furthermore, the review will indicate
patient-related and healthcare-related factors that should be addressed to improve on survival of patients with
MDR-TB/HIV co-infection in LMICs.
Systematic review registration: This review has been registered with the International Prospective Register of
Systematic Reviews and the reference ID is CRD42020159745
Keywords: Integrated treatment, HIV, Multidrug-resistant tuberculosis, Outcomes
Background
Tuberculosis (TB) is a leading cause of mortality world-
wide and the highest burden is in low-and middle-
income settings [1]. In these settings, mortality from TB
is greatest among persons living with HIV/AIDS (PLWH
A) [1, 2]. Some progress has been made in addressing
this issue through the introduction and progressive
scale-up of integrated treatment of TB and HIV [3]. The
aim of the intervention is to secure efficient treatment
services and maximize successful treatment outcomes
for TB/HIV co-infection through the delivery of both
anti-retroviral and anti-tuberculous drugs at the same
time and location by one healthcare team or provider.
While acknowledging the intended role of treatment in-
tegration in reducing the burden of TB in PLWHA [4,
5], the scale-up of the intervention is confronted by an
important challenge: the emergence and spread of multi-
drug-resistant tuberculosis (MDR-TB). This form of TB
occurs when Mycobacterium tuberculosis cannot be
killed by isoniazid and rifampin; the two best antibiotics
that are most commonly used to treat TB [6, 7]. MDR-
TB primarily results from mismanagement of treatment
(as in poor treatment adherence and use of low-quality
drugs) and person-to-person transmission of the resist-
ant strains which ultimately persist in the population [7].
The survival and spread of the resistant strains are po-
tentiated by a global lack of appropriate measures to de-
tect and treat them promptly [8]. Overall, MDR-TB is
more complicated and expensive to treat than the ordin-
ary drug-sensitive TB [9]. It remains an important bar-
rier to successful TB treatment and in 2018, 500,000
new cases of MDR-TB were recorded worldwide [1].
While novel strategies are being designed and invest-
ments made to scale-up the delivery of integrated
treatment for TB/HIV, there remains a huge knowledge
gap on treatment outcomes of MDR-TB within pro-
grams integrating TB/HIV treatment in low- and
middle-income settings where the burden of TB/HIV
co-infection is highest. Previous studies have generally
focused on the potential of integrated TB/HIV treatment
programs to sustain successful TB treatment outcomes
in patients co-infected with HIV and drug-sensitive tu-
berculosis. A recent systematic review by Chem et al. in-
vestigated treatment outcomes in patients co-infected
with MDR-TB and HIV in sub-Saharan Africa (SSA)
and found that whilst MDR-TB treatment outcomes are
comparable to those reported globally, successful out-
comes are much lower in patients who are co-infected
with HIV [10]. Notwithstanding these pertinent findings,
the review was limited to SSA [10] whilst recent global
reports indicate relatively higher rates of TB in general
and MDR-TB in particular in low-income Asian settings
compared to SSA [11], albeit these observations may be
due to under-diagnosis or under-reporting which remain
serious problems in SSA. Furthermore, an important ob-
jective of integrating TB/HIV treatment programs is to
start anti-TB drugs early for PLWHA who are diagnosed
with TB, with the intent of limiting progression to more
severe TB and improve survival. However, a recent sys-
tematic review by Harris et al. noted that evidence sup-
porting the superiority in the effectiveness of early
initiation of treatment of MDR-TB over that of delayed
treatment is insufficient [12]. Evidence on other factors
that could predict MDR-TB treatment outcomes in the
general population and in PLWHA more specifically, are
also poorly understood. Broader perspectives into the
potential of TB/HIV integrated treatment services in
LMICs to uphold successful MDR-TB outcomes can be
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derived by synthesising evidence on both MDR-TB treat-
ment outcomes and predictors of these outcomes when
TB/HIV services are integrated in LMICs. These will
help formulate strategies to better equip integrated treat-
ment programs for the effective management of MDR-
TB/HIV co-infection and increase MDR-TB treatment
success.
Objectives
1. To synthesise quantitative estimates of treatment
outcomes of MDR-TB in adults receiving integrated
treatment for TB and HIV in LMICs.
2. To determine the predictors of MDR-TB treatment
outcomes in this population.
Methods
In order to attain our objectives, the following steps will
be followed:
1. Development of a literature search strategy to
identify evidence on MDR-TB treatment outcomes
among adults receiving integrated therapy for TB/
HIV in LMICs.
2. Screening of all the identified studies in objective 1
for their relevance in addressing the research
objectives.
3. Critical appraisal of the evidence obtained from
studies retained from objective 2
4. Extraction of relevant data from studies in [3] on
treatment outcomes of MDR-TB and their predic-
tors in adults receiving integrated treatment for TB/
HIV in LMICs.
5. Meta-analysis (if justified) of the evidence obtained
in [4].
Search strategy
MEDLINE, Embase, Global Health, and Cochrane elec-
tronic databases will be searched extensively to include
studies published between March 2004 (when the World
Health Organization issued the first guidelines on TB
and HIV collaborative activities) and December 2019. A
data extraction form and definition of key terms will be
developed to standardise the data collection process.
The search terms and their variations will be used in
combination as shown on Table 1. Articles retrieved
from the search will be saved on Mendeley desktop soft-
ware and their titles and abstracts (including those in
reference lists of relevant articles) will be screened. Fol-
lowing the screening, studies that fulfil the inclusion cri-
teria and adequately address the research objectives shall
be retained for full-text review. The reference lists of in-
cluded studies and previous reviews will be explored to
identify other eligible studies.
Selection criteria
The study will include peer-reviewed quantitative and
mixed methods studies describing MDR-TB treatment
outcomes and their predictors in the context of inte-
grated TB/HIV treatment in LMICs. These studies will
include observational cohort and case control studies
published in the English language. BMK and DA will in-
dependently assess retrieved titles and abstracts of rele-
vant studies for their eligibility to be included in the
review. They will then perform independent screening of
the full texts of retained articles. Conference abstracts,
editorials, letters to the editor, bulletins, and grey litera-
ture shall be excluded. Disagreements between the two
investigators will be resolved by arbitration by a third in-
vestigator (CAD). Table 2 shows the inclusion and ex-
clusion criteria set for the study. These criteria were
defined using the PICOS (Population, Intervention,
Comparator, Outcome, Study design) approach.
Data extraction and analysis
Relevant data will be extracted from each eligible article
retained for full-text review. The extracted data will be
saved on a Microsoft Excel 2016 form and subsequently
double-checked for accuracy by the investigators. The
data to be extracted include the following:
1. Publication details: name of first author, publication
year, journal reference, country, and place of study,
year of study, study design, study area and setting,
study population, sample size, characteristics of
study participants (such as age and sex
distribution), as well as limitations and strengths of
studies.
2. Outcomes of interest: Treatment outcomes of
multi-drug-resistant pulmonary TB as defined by
the World Health Organisation (WHO): cured,
treatment completed, defaulted, and mortality [12,
13]. Multi-drug-resistant TB is considered when
Mycobacterium tuberculosis cannot be killed by at
least isoniazid and rifampin [6, 7, 10]. Cure is de-
fined as the presence of a negative sputum smear at
the last month of treatment and at least on one
Table 1 Search strategy for systematic review
Search # Search query
1 Integrat* OR joint OR collaborat* OR concurrent OR
concomitant
2 Treat* OR therap* OR care OR service OR manag*
3 ‘Human immun?deficiency virus’ OR HIV OR HIV1 OR
HIV2 OR AIDS OR ‘Acquired immune?deficiency
syndrome’ OR anti?retroviral
4 Tuberculosis OR ‘Mycobacterium tuberculosis’ OR
‘Pulmonary tuberculosis’ OR TB OR anti?tubercul*
5 #1 AND #2 AND #3 AND #4
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other occasion during treatment. Treatment com-
pletion is the term used to describe a patient who
completed treatment, but for whom smear examin-
ation results were not complete enough to classify
the patient as cured; or based on clinical, radio-
logical and complementary examination criteria in
those patients who did not produce sputum for a
smear examination. Death refers to all-cause mor-
tality occurring after TB diagnosis and before the
end of treatment. A defaulter is one who fails to
collect medicines for ≥ 2 consecutive months. Ac-
cording to the guidelines, successful treatment out-
comes refer to the combination of ‘cure’ and
‘treatment completed’ categories. As per the WHO
classification, successful treatment refers to cases of
treatment completion and cure [12, 13]. Measures
of frequency and central tendency referring to these
outcom,es will be recorded as well. Predictors of
treatment outcomes will be considered as all vari-
ables which studies will report as having an associ-
ation with MDR-TB treatment outcomes. Data on
predictors of each of the WHO TB treatment out-
comes will be extracted.
BMK and DA will independently assess the quality of
quantitative evidence from quantitative and mixed
methods studies using appropriate tools in the National
Heart, Lung and Blood Institute (NHLBI). Disagree-
ments in the quality of studies will be resolved by arbi-
tration by a third investigator (CAD). Data extracted
from the retained studies will be recorded on Microsoft
Excel 2016 and quantitative data exported to STATA 15.
Random-effects meta-analysis will be used to analyse
and synthesise data on treatment outcomes. For predic-
tors of treatment outcomes, random-effects meta-
analysis will be performed to obtain pooled effect esti-
mates summarizing data on predictors of each of the
four treatment outcomes, i.e. cure, treatment comple-
tion, defaulted, and death. Any test statistic that can be
converted to effect size will be considered but we antici-
pate that correlation and regression coefficients will be
the most reported measure of effect and will therefore
be the effect sizes of primary interest in the review. For
studies that report odds ratios, the log odds will be cal-
culated prior to pooling the effect sizes. In order to ex-
plore the possible effects of confounding, separate
analyses will be performed for adjusted and unadjusted
effect estimates. When methodological limitations could
potentially explain the effect size in a study, sensitivity
analysis will be conducted by omitting the study and re-
peating the meta-analysis. Data on treatment outcomes
and effect of predictors will be represented on forest
plots and risk of bias will be assessed using funnel plots.
The degree of variability in this data will be assessed by
visual inspection of the forest plots and interpretation of
the I2 statistic from meta-analyses. Based on the I2 statis-
tic, the degree of variability or heterogeneity will be
interpreted as none (I2 < 25%), low (25 ≤ I2 ≤ 49%),
moderate (50 ≤ I2 ≤ 74%), or high (I2 ≥ 75%). For each
treatment outcome, the p-value for heterogeneity shall
be used to determine whether the heterogeneity is asso-
ciated with variations in the observed effect size across
Table 2 Selection criteria for studies to be included in systematic review of therapeutic outcomes of multi-drug-resistant
tuberculosis and their predictors in adults receiving integrated treatment of tuberculosis and human immuno-deficiency virus in
low- and middle-income countries
Item Inclusion criteria Exclusion criteria
Population Studies involving adults who are co-infected
with MDR-TB and HIV in LMICs
Studies involving
-Pregnant women
-Patients with multi-morbidities
Intervention Studies reporting on the delivery of integrated
treatment of TB and HIV in LMICs
-Studies describing treatment of only MDR-TB
-Studies describing integrated treatment of drug-sensitive
TB and HIV
-Studies describing integrated treatment of more than 2
diseases (TB/HIV)
Comparison
Outcome(s) Studies reporting on MDR-TB outcomes and/or their
predictors in the setting of integrated therapy for TB/HIV.
Studies describing outcomes that are unrelated to treatment
of MDR-TB in the context of integrated TB/HIV therapy
Study design Observational studies specifically, cohort
studies that use quantitative research methods
1) Interventional studies
2) Observational studies other than cohort,
e.g. cross-sectional studies
3) Mini-reviews, conference abstracts, letters to editors,
editorials, commentaries.
4) Studies whose full data will not be available even upon
requesting from the author
5) Duplicates studies: for studies published with the same or
different titles or in more than one journal, the most updated
version shall be considered.
Kadia et al. Systematic Reviews           (2020) 9:228 Page 4 of 6
studies. In case of variability I2 > 50% in the effect of
predictors, the latter will be synthesised using a qualita-
tive approach. Where possible, meta-regression will be
used to assess the effect of variations in sample size,
study design, and geographical location on summary es-
timates. All reported p values will be two-sided with a
significance level of 0.05. The confidence in the sum-
mary estimates will be rated using criteria of the Grading
of Recommendations, Assessment, Development and
Evaluation (GRADE) approach [14].
Reporting
This protocol has been reported in accordance with the
Preferred Reporting Items for Systematic Reviews and
Meta-Analysis Protocol (PRISMA-P) [15, 16] (supple-
mentary file 1).
Systematic review registration
This review has been registered with the International
Prospective Register of Systematic Reviews and the refer-
ence ID is CRD42020159745.
Discussion
There is paucity of evidence on therapeutic outcomes of
MDR-TB/HIV co-infection when managed within TB/
HIV integrated treatment programs in LMICs. This re-
view will involve a systematic collection, critical ap-
praisal and synthesis of evidence on therapeutic
outcomes of MDR-TB among adults receiving integrated
treatment for TB/HIV in LMICs. This study will report
the performance of integrated TB/HIV treatment pro-
grams in LMICs by describing the potential of these pro-
grams to uphold successful outcomes among MDR-TB/
HIV co-infected patients. Furthermore, the study will
discuss factors that should be addressed to improve on
survival of patients with MDR-TB/HIV co-infection who
receive integrated treatment in LMICs. The final review
will be presented at scientific conferences and published
in a peer-reviewed journal.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13643-020-01493-5.
Additional file 1. PRISMA-P 2015 checklist for protocol on systematic
review of therapeutic outcomes of MDR-TB and their predictors in adults
receiving integrated treatment of tuberculosis and Human Immuno-
deficiency Virus in low and middle-income countries.
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